Daxor Announces Publication of 3 Studies in Heart Failure Patients and Cardiac Bypass Patients with the BVA-100 Blood Volume Analyzer.

Business Editors

NEW YORK--(BUSINESS WIRE)--Feb. 6, 2003

Daxor Corporation (AMEX:DXR), a leading medical instrumentation and biotechnology company, today announced that two new studies conducted at the Columbia Presbyterian Medical Center, #1 ranked hospital in the NY region, were published in the medical journal Circulation, (Circulation.2003;107:294-299). The first study, authored by Dr. Ana-Silvia Androne, Dr. Stuart Katz, et al, utilized the Daxor BVA-100 Blood Volume Analyzer to measure the degree of blood volume expansion in congestive heart failure patients. They compared their findings to an independent physician's estimate of whether the patients had significant expanded blood volume or were normal. In half the heart failure patients, the physicians were not able to detect the abnormal expanded blood volume. The implications of these findings are that blood volume measurement can enable more precise treatment in patients. Congestive heart failure patients are treated with diuretics to remove excessive blood volume. Over treatment with diuretics can be just as harmful as under treatment in improving patients' conditions.

The second study published in the same journal authored by Dr. Donna M. Mancini, Dr. Stuart Katz, et al, involves the treatment of heart failure patients who were found to be anemic by the standard hematocrit test. The standard hematocrit only measures the concentration of red blood cells in relation to plasma, but does not inform the treating physician of the actual volume of red blood within the patient's circulation. The authors found that treatment of these patients with Erythropoetin significantly improved the symptoms of these patients. Blood volume measurement with the BVA-100 also enabled identification of those patients who were hemodiluted and had increased plasma volume from those patients who were truly anemic and had low red cell volume. Erythropoetin, manufactured by Amgen and Johnson & Johnson, is a restricted drug which increases a patient's red cell volume. The measurement of blood volume has implications for the treatment of patients who may be inappropriately denied treatment because their blood volume is not measured.

A third study was published in the November 2002 issue of the Journal of Clinical Anesthesia by Ketan Shevde, MD, Murali Pagala, PhD, et al, from Maimonides Hospital, involving patients undergoing coronary bypass graft surgery. The patients had their blood volume measured with the BVA-100 prior to surgery. Women were found to be significantly more anemic than men and required more blood transfusions. The authors concluded that the increased number of transfusions required for women was related to their low red cell volume prior to surgery.

Dr. Joseph Feldschuh, President of Daxor, who is a cardiologist, stated that "At the present time it is very difficult for physicians to judge when they have over treated or under treated patients. Congestive heart failure is the #1 cause for admission of patients over the age of 65 into hospitals. More precise treatment has the potential for reducing the frequency and extent of hospitalization of congestive heart failure patients. The study at Maimonides suggests that where surgery is not immediately required, patients, particularly women, may benefit from blood volume measurement and aggressive treatment with Erythropoetin to increase their red cell volume prior to surgery."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit. It is the first instrument to provide rapid, direct measurement of a patient's blood volume with a high degree of precision. Among nationally renowned hospitals using the BVA-100 Blood Volume Analyzer are NYU Medical Center, The Mayo Clinic and The Cleveland Clinic, as well as other major medical institutions. More information about the BVA-100 and other Daxor products and services can be found at www.daxor.com.